Evidence map›Paper›PMID 38553691›Full record

ArticleBMC health services research2024

Evaluation of heroin-assisted treatment in Norway: protocol for a mixed methods study.

Lars Henrik Myklebust, Desiree Eide, Espen A Arnevik, Omid Dadras, Silvana De Pirro, Rune Ellefsen, Lars T Fadnes, Morten Hesse, Timo L Kvamme, Francesca Melis and 4 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Lars Henrik MyklebustNorwegian Centre for Addiction Research, Faculty of Medicine, University of Oslo, Kirkevegen 166, Building 45, NO-0407, Oslo, Norway. l.h.r.myklebust@medisin.uio.no.
Desiree EideNorwegian Centre for Addiction Research, Faculty of Medicine, University of Oslo, Kirkevegen 166, Building 45, NO-0407, Oslo, Norway.
Espen A ArnevikSection for Clinical Addiction Research, Oslo University Hospital, P.b 4950 Nydalen, NO-0424, Oslo, Norway.
Omid DadrasBergen Addiction Research Group, Department of Addiction Medicine, Haukeland University Hospital, P.b 1400, NO-5021, Bergen, Norway.
Silvana De PirroNorwegian Centre for Addiction Research, Faculty of Medicine, University of Oslo, Kirkevegen 166, Building 45, NO-0407, Oslo, Norway.
Rune EllefsenSection for Clinical Addiction Research, Oslo University Hospital, P.b 4950 Nydalen, NO-0424, Oslo, Norway.
Lars T FadnesBergen Addiction Research Group, Department of Addiction Medicine, Haukeland University Hospital, P.b 1400, NO-5021, Bergen, Norway.
Morten HesseCentre for Alcohol and Drug Research, Aarhus University, Bartholins Allé 10, DK-8000, Aarhus, Denmark.
Timo L KvammeCentre for Alcohol and Drug Research, Aarhus University, Bartholins Allé 10, DK-8000, Aarhus, Denmark.
Francesca MelisNorwegian Centre for Addiction Research, Faculty of Medicine, University of Oslo, Kirkevegen 166, Building 45, NO-0407, Oslo, Norway.
Ann OldervollNorwegian Centre for Addiction Research, Faculty of Medicine, University of Oslo, Kirkevegen 166, Building 45, NO-0407, Oslo, Norway.
Birgitte ThylstrupCentre for Alcohol and Drug Research, Aarhus University, Bartholins Allé 10, DK-8000, Aarhus, Denmark.
Linda E C WusthoffNorwegian Centre for Addiction Research, Faculty of Medicine, University of Oslo, Kirkevegen 166, Building 45, NO-0407, Oslo, Norway.
Thomas ClausenNorwegian Centre for Addiction Research, Faculty of Medicine, University of Oslo, Kirkevegen 166, Building 45, NO-0407, Oslo, Norway.
University of Oslo · NOAarhus University · DKOslo University Hospital · NOHaukeland University Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOpioid agonist treatment (OAT) for patients with opioid use disorder (OUD) has a convincing evidence base, although variable retention rates suggest that it may not be beneficial for all. One of the options to include more patients is the introduction of heroin-assisted treatment (HAT), which involves the prescribing of pharmaceutical heroin in a clinical supervised setting. Clinical trials suggest that HAT positively affects illicit drug use, criminal behavior, quality of life, and health. The results are less clear for longer-term outcomes such as mortality, level of function and social integration. This protocol describes a longitudinal evaluation of the introduction of HAT into the OAT services in Norway over a 5-year period. The main aim of the project is to study the individual, organizational and societal effects of implementing HAT in the specialized healthcare services for OUD.

methodsThe project adopts a multidisciplinary approach, where the primary cohort for analysis will consist of approximately 250 patients in Norway, observed during the period of 2022-2026. Cohorts for comparative analysis will include all HAT-patients in Denmark from 2010 to 2022 (N = 500) and all Norwegian patients in conventional OAT (N = 8300). Data comes from individual in-depth and semi-structured interviews, self-report questionnaires, clinical records, and national registries, collected at several time points throughout patients' courses of treatment. Qualitative analyses will use a flexible inductive thematic approach. Quantitative analyses will employ a wide array of methods including bi-variate parametric and non-parametric tests, and various forms of multivariate modeling. DISCUSSION: The project's primary strength lies in its comprehensive and longitudinal approach. It has the potential to reveal new insights on whether pharmaceutical heroin should be an integral part of integrated conventional OAT services to individually tailor treatments for patients with OUD. This could affect considerations about drug treatment even beyond HAT-specific topics, where an expanded understanding of why some do not succeed with conventional OAT will strengthen the knowledge base for drug treatment in general. Results will be disseminated to the scientific community, clinicians, and policy makers.

trial registrationThe study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK), ref.nr.:195733.

Indexed as

HeroinOpioid-Related DisordersAnalgesics, OpioidClinical Studies as TopicHumansNorwayPharmaceutical PreparationsQuality of LifeAnalgesics, OpioidHeroinPharmaceutical PreparationsHealth servicesHeroin assisted treatmentLongitudinalMixed methodsOpioid maintenance treatmentProtocol

Identifiers

PMID38553691
PMCPMC10981318
OpenAlexW4393317842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.